CD4 and tuberculosis: There is a lack of conventional efficacy data in support of a particular dose or target pharmacokinetic parameter for rifabutin [24], but there is convincing evidence that intermittent rifamycin therapy is associated with tuberculosis relapse and rifamycin resistance, especially in subjects with low CD4 counts [17, 18, 25–27].